Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Temp set back for $AERI today...
Looking better. Gonna be a long haul back up though
News: $AERI Aerie Pharmaceuticals Inc (AERI) Q2 2020 Earnings Call Transcript
Image source: The Motley Fool. Aerie Pharmaceuticals Inc (NASDAQ: AERI) Q2 2020 Earnings Call Aug 7, 2020 , 11:00 a.m. ET Operator Continue reading
Find out more AERI - Aerie Pharmaceuticals Inc (AERI) Q2 2020 Earnings Call Transcript
Tempted to buy more here - but holding off
Here’s hoping. Seems oversold and we rentered
News: $AERI Aerie Pharmaceuticals Inc. (NASDAQ:AERI) Short Squeeze
Over the past twenty days of trading, Aerie Pharmaceuticals Inc. (NASDAQ: AERI), from October 30, 2019 to November 26, 2019 there is a potential Sh...
Got this from AERI - Aerie Pharmaceuticals Inc. (NASDAQ:AERI) Short Squeeze
$AERI good read Aerie Pharmaceuticals Inc Nasdaq Aeri Short Squeeze
Oh boy. 250 mil raise on the way. Should be a screaming but now. Stock pps with 2 blockbuster approvals lower than with none. There has been a bit of dilution though.
Very tough bringing drugstore to market even if they are blockbuster status
Looks like a fantastic buy right now for those with patience. Cash burn rough if they keep up the market it themselves model.
First purchase here was 11 sold at 35. Bought back at 17 sold most of position at 69 average although hung on to 3000 shares thinking it was going to 100 in a buyout.
This stock has been great and will be again
They would be smart to acquire EYEN to become the force d' major
News: $AERI Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial in Japan Designed to Support Requirements for Future Regulatory Filing
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announ...
Got this from https://marketwirenews.com/news-releases/aerie-pharmaceuticals-initiates-netarsudil-ophthalmic-solution-phase-2-clinical-trial-in-japan-designed-to-support-requirements-for-future-regulatory-filing-7860488.html
$80.00 pps in latest coverage. Puts it at near 4 bil market cap if it happens
Sure sounds like they are going to market the new drug themselves once approved. Hope not. Approval will Either an optimal time for a deal or to exit stock. It has been a very very good investment.
recovered $10.00 in a week. With deals heating up this worth a look, off high of 70 and second product could be approved anytime first half
AERI coverage just keeps getting better.
Aerie Pharmaceuticals May Revolutionize Glaucoma Treatmenthttps://finance.yahoo.com/news/aerie-pharmaceuticals-may-revolutionize-glaucoma-110100052.html
This puppy could hit 100 next year, that would make it a 10 bagger. Can't wait to hear whats up on earnings call
Second drug looks to be much improved. Some are saying they still could be bought out although their actions are not encouraging.
They are raising 75 mil more and going forward hiring salespeople. They should be a take out target and only having one product that is new is a difficult sell. Even if a Company like Allergan bought them AGN would lose money the first 24 months.
At least they are raising money in the most responsible way a Company can do it.
we were in at 9 average out at 33, went back in 1t 16 and out at 65. All in 2 years. back in at 58 for a smaller amount.
Seems like Buyout is the only option now. Most of Bios now are sell the approval or News or Offering
WOW... what timimg.. AERI halted and drug approved 2 months early. Most likely no warning label.
WOW WOW WOW
Back in - still concerned about labeling but AERI could be a prime take out with tax reform. If not, will be out when news breaks from FDA
Just a few months to go for the big news. I have been an Aeri supporter for almost 2 years. Bought at 10 sold at 32, rebought at 17 sold at average of 62.
Entered very small at 59.
What is problematic is the lack of deals and mergers being done. They look to have 2 superstar blockbusters and the stock may very well be 80 to 100 if a buyout were to occur.
That is less likely though as they are hiring their own sales force. Not only does that present the problem of salesman having a one trick pony product for now, but they have zero experience running a sales team. Even hiring experienced people from big pharma is not encouraging as they are use to having a portfolio of drugs, established relationships and a huge marketing budget. There is a possibility of the product having a label as well.
This is not a Gilead situation where a drug takes over a market immediately. Most small biotech’s lose money for at least 3 years, and lose a lot of money. Aeri could bled 100’s if millions of dollars before it reaches us profitable, and the over under on pivoting to profits is 3.5 years.
The upside is that Aeri could be a billion dollar drug, or more. We bought Aeri for turnaround and buyout just like rite aid, Salix, Receptos, Sarepta BMY.
Aeri seemed a perfect fit for AGN, but it is not looking like that now. Tax reform doesn’t benefit AGN. Maybe they will get bought out but not optimistic at this point.
Analysts now calling up to 80. Might buy back now that things have settled in
Hopefully approved without a label.
Upon reading the one no vote is very bad because that opinion is bad. Thinking gap up and approval but label will be curious. Waiting for press release.
Oops. Sold to soon. Great news. Safety received a 9 to 1 positive bote
In since $11.00. Time to say goodbye for now.
This is at 2.3 bil market cap. A billion dollar drug could push this to 100 but happy with 2 yr win. Might buy on dips
Meeting is on, my reading is drug is effective and discussion will be about safety
Aeri flying. Data so good no need for fda review friday
Good day for Aeri. Maybe profit taking over in anticipation of Friday.
Big day Friday. Was a steal when dipped under 50
The FDA's Dermatologic and Ophthalmic Drugs Advisory Committee will meet on October 13 to review and discuss Aerie Pharmaceuticals' (AERI -5.5%) New Drug Application seeking approval for Rhopressa (netarsudil ophthalmic solution) to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
The FDA's action date is February 28, 2018.
Decent correction. Upcoming FDA will be huge. Could be moderate safety profile issue, if not will be interesting where the next leg takes this
Hit new high this week. Not a bad run from first buying at $9.00
Next month big meeting with FDA...Fingers crossed.
Still holding, bought at 9 sold at 32. Bought back at 16. Eventually there will be pharma but it's again and this is still attractive
I wonder where those shorts bought back how much did they lose?
Check this out
RDHL has1 NDA filling & 2 phase 3 results due by 6/30/2017 + 1 phase 2 due due by 7/31/2017///
we always thought they would be a good buyout candidate.. 2017 might be the year
Looks good daily weekly and monthly...keep pulling in the profits!
...nice ascending triangle breakout pattern here...good things in store... http://goo.gl/i0RzyE
Nearly touched 45.... we got in at 8 Good things siillmto come
How is short position going? Been in big time since the first collapse to 9 and loaded the bus. instinct tells me this will get some type of offer with a 6 or higher in front of it in 2017. could correct a little first but the data seems pretty good.
Is this the new Seth Shaw pump job?
ROTFLMAO
It's being touted on other boards...
So I'm guessing it is...
OUch....:). I don't think Inwould be hopping on the short train just yet. We got in on a the first massive drop, from 33 to 8 in a day. That was based on bad results due to such a big reach, as soon as they amended it popped right back to the 30's. The recent drop was the whole biotech sector getting clobbered with the Valeant mess. now they have submitted and also have another promising drug.
I think you are going to see some of the big dogs go on buying spree again, AGN, PFE GILD. This is right in AGN's wheelhouse for both drugs
Just added to my short position. This has been pumped on HOT AIR
go short, eventually it will crash hard
Followers
|
9
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
157
|
Created
|
10/30/13
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |